Cyprotex PLC is a holding company. The Company�s trading subsidiaries are Cyprotex Discovery Limited and Apredica LLC. The principal activities of the Company are that of providing in vitro and in silico ADMET and PK (Absorption, Distribution, Metabolism, Excretion, Toxicity and Pharmacokinetics) information to the pharmaceutical and biotechnology industries. Cyprotex provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. Cyprotex serves all types and sizes of drug-discovery organizations, as well as academic and not-for-profit laboratories. In January 2014, the Company acquired business and assets of CeeTox, Inc, a division of North American Science Associates, Inc.